The latest Market Talks covering the Health Care sector. Published exclusively on Dow Jones Newswires at 4:20 ET, 12:20 ET and 16:50 ET.
1435 GMT – Fresenius SE’s third-quarter results continue its robust 2025 run, Citi analysts write in a note, after the German healthcare group reported higher revenue and earnings for the quarter. “We are encouraged by the strong operational performance across both Kabi and Helios,” the analysts say, referring to Fresenius’s pharmaceutical and hospital business units. Citi has a buy rating and a 52 euro target on the stock. Shares trade flat at 48.52 euros. (william.gray@wsj.com)
Copyright ©2025 Dow Jones & Company, Inc. All Rights Reserved. 87990cbe856818d5eddac44c7b1cdeb8